| TDSGF Stock | | | USD 0.07 0.01 13.58% |
Founder
Sabine Mai is Member Founder of Telo Genomics Corp since 2018.
| Tenure | 6 years |
| Phone | 416 673 8487 |
| Web | https://www.telodx.com |
Telo Genomics Management Efficiency
The company has return on total asset
(ROA) of
(0.454) % which means that it has lost $0.454 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(0.7783) %, meaning that it generated substantial loss on money invested by shareholders. Telo Genomics' management efficiency ratios could be used to measure how well Telo Genomics manages its routine affairs as well as how well it operates its assets and liabilities.
Telo Genomics Corp has accumulated 40
K in total debt with debt to equity ratio
(D/E) of 0.02, which may suggest the company is not taking enough advantage from borrowing. Telo Genomics Corp has a current ratio of 14.37, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Telo Genomics until it has trouble settling it off, either with new capital or with free cash flow. So, Telo Genomics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Telo Genomics Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Telo to invest in growth at high rates of return. When we think about Telo Genomics' use of debt, we should always consider it together with cash and equity.
Similar Executives
Telo Genomics Corp., a biotech company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions. Telo Genomics Corp. was incorporated in 2014 and is headquartered in Toronto, Canada. TELO GENOMICS is traded on OTC Exchange in the United States. Telo Genomics Corp [TDSGF] is traded as part of a regulated electronic over-the-counter service offered by the NASD.
Management Performance
Telo Genomics Corp Leadership Team
Elected by the shareholders, the Telo Genomics' board of directors comprises two types of representatives: Telo Genomics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Telo. The board's role is to monitor Telo Genomics' management team and ensure that shareholders' interests are well served. Telo Genomics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Telo Genomics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Telo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Telo Genomics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Other Information on Investing in Telo OTC Stock
Telo Genomics financial ratios help investors to determine whether Telo OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Telo with respect to the benefits of owning Telo Genomics security.